- $7.74m
- $8.90m
- $0.21m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 50.55 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -2733.49% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.38 | 0.24 | 0.12 | 0.05 | 0.21 | n/a | n/a | -20.11% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. Its BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained-release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.
Directors
- Brady Granier PRE (48)
- Lourdes Felix CEO (53)
- Thomas Welch EVP (49)
- Kent Emry IND (52)
- Joseph Galligan IND (61)
- Louisa Ingargiola IND (47)
- Louis Lucido IND (72)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- January 28th, 2008
- Public Since
- August 31st, 2010
- No. of Shareholders
- 144
- No. of Employees
- 5
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 8,599,076
- Address
- 2390 East Orangewood Avenue, Suite 500, ANAHEIM, 92806
- Web
- https://www.biocorrx.com/
- Phone
- +1 7144624880
- Auditors
- Marcum LLP
Upcoming Events for BICX
Q1 2024 BioCorRx Inc Earnings Release
Q2 2024 BioCorRx Inc Earnings Release
Similar to BICX
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
ACI Global
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
FAQ
As of Today at 18:04 UTC, shares in Biocorrx are trading at $0.90. This share price information is delayed by 15 minutes.
Shares in Biocorrx last closed at $0.90 and the price had moved by -41.94% over the past 365 days. In terms of relative price strength the Biocorrx share price has underperformed the S&P500 Index by -53.25% over the past year.
There is no consensus recommendation for this security.
Biocorrx does not currently pay a dividend.
Biocorrx does not currently pay a dividend.
Biocorrx does not currently pay a dividend.
To buy shares in Biocorrx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.90, shares in Biocorrx had a market capitalisation of $7.74m.
Here are the trading details for Biocorrx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BICX
Based on an overall assessment of its quality, value and momentum Biocorrx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocorrx. Over the past six months, its share price has underperformed the S&P500 Index by -56.2%.
As of the last closing price of $0.90, shares in Biocorrx were trading -38.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biocorrx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biocorrx's management team is headed by:
- Brady Granier - PRE
- Lourdes Felix - CEO
- Thomas Welch - EVP
- Kent Emry - IND
- Joseph Galligan - IND
- Louisa Ingargiola - IND
- Louis Lucido - IND